Landos Biopharma Analyst Ratings
Landos Biopharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/06/2023 | -81.57% | Jefferies | $0.2 → $0.1 | Downgrades | Hold → Underperform |
| 11/11/2022 | 268.66% | SVB Leerink | $3 → $2 | Maintains | Market Perform |
| 08/12/2022 | 453% | SVB Leerink | $16 → $3 | Maintains | Market Perform |
| 08/12/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 04/12/2022 | 158.06% | Jefferies | $30 → $1.4 | Downgrades | Buy → Hold |
| 03/25/2022 | 1558.99% | Raymond James | $24 → $9 | Maintains | Outperform |
| 01/03/2022 | 1190.32% | JP Morgan | $15 → $7 | Maintains | Neutral |
| 11/16/2021 | 2849.31% | SVB Leerink | $20 → $16 | Downgrades | Outperform → Market Perform |
| 10/20/2021 | 8194.93% | Craig-Hallum | → $45 | Initiates Coverage On | → Buy |
| 10/19/2021 | 9116.59% | HC Wainwright & Co. | → $50 | Initiates Coverage On | → Buy |
| 09/23/2021 | 7088.94% | JonesTrading | → $39 | Initiates Coverage On | → Buy |
| 07/30/2021 | 6351.61% | Raymond James | $33 → $35 | Maintains | Outperform |
| 03/01/2021 | 5798.62% | Jefferies | → $32 | Initiates Coverage On | → Buy |
| 03/01/2021 | 3033.64% | JP Morgan | → $17 | Initiates Coverage On | → Neutral |
| 03/01/2021 | 5982.95% | Raymond James | → $33 | Maintains | Outperform |
| 03/01/2021 | 3586.64% | SVB Leerink | → $20 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 01/06/2023 | -81.57% | 杰富瑞 | $0.2→$0.1 | 评级下调 | 持有→表现不佳 |
| 2022年11月11日 | 268.66% | SVB Leerink | $3→$2 | 维护 | 市场表现 |
| 2022年08月12日 | 453% | SVB Leerink | $16→$3 | 维护 | 市场表现 |
| 2022年08月12日 | - | 雷蒙德·詹姆斯 | 评级下调 | 跑赢→市场表现 | |
| 04/12/2022 | 158.06% | 杰富瑞 | $30→$1.4 | 评级下调 | 购买→Hold |
| 03/25/2022 | 1558.99% | 雷蒙德·詹姆斯 | $24→$9 | 维护 | 跑赢大盘 |
| 01/03/2022 | 1190.32% | 摩根大通 | $15→$7 | 维护 | 中性 |
| 2021年11月16日 | 2849.31% | SVB Leerink | $20→$16 | 评级下调 | 跑赢→市场表现 |
| 10/20/2021 | 8194.93% | 克雷格-哈勒姆 | →$45 | 开始承保 | →购买 |
| 10/19/2021 | 9116.59% | HC Wainwright公司 | →$50 | 开始承保 | →购买 |
| 09/23/2021 | 7088.94% | Jones Trading | →$39 | 开始承保 | →购买 |
| 07/30/2021 | 6351.61% | 雷蒙德·詹姆斯 | $33→$35 | 维护 | 跑赢大盘 |
| 03/01/2021 | 5798.62% | 杰富瑞 | →$32 | 开始承保 | →购买 |
| 03/01/2021 | 3033.64% | 摩根大通 | →$17 | 开始承保 | →中性 |
| 03/01/2021 | 5982.95% | 雷蒙德·詹姆斯 | →$33 | 维护 | 跑赢大盘 |
| 03/01/2021 | 3586.64% | SVB Leerink | →$20 | 开始承保 | →跑赢大盘 |
What is the target price for Landos Biopharma (LABP)?
兰多斯生物医药(LABP)的目标价格是多少？
The latest price target for Landos Biopharma (NASDAQ: LABP) was reported by Jefferies on January 6, 2023. The analyst firm set a price target for $0.10 expecting LABP to fall to within 12 months (a possible -81.57% downside). 6 analyst firms have reported ratings in the last year.
杰富瑞于2023年1月6日报道了Landos Biophma(纳斯达克：LABP)的最新目标价。这家分析公司将目标价定为0.10美元，预计LABP将在12个月内降至(可能下跌81.57%)。6家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Landos Biopharma (LABP)?
兰多斯生物医药(LABP)的最新分析师评级是多少？
The latest analyst rating for Landos Biopharma (NASDAQ: LABP) was provided by Jefferies, and Landos Biopharma downgraded their underperform rating.
杰富瑞对Landos Biophma(纳斯达克股票代码：LABP)的最新分析师评级，下调了其表现不佳的评级。
When is the next analyst rating going to be posted or updated for Landos Biopharma (LABP)?
兰多斯生物医药(LABP)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Landos Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Landos Biopharma was filed on January 6, 2023 so you should expect the next rating to be made available sometime around January 6, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Landos Biophma的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Landos Biophma的上一次评级是在2023年1月6日提交的，所以你应该预计下一次评级将在2024年1月6日左右的某个时候公布。
Is the Analyst Rating Landos Biopharma (LABP) correct?
分析师对Landos Biophma(LABP)的评级正确吗？
While ratings are subjective and will change, the latest Landos Biopharma (LABP) rating was a downgraded with a price target of $0.20 to $0.10. The current price Landos Biopharma (LABP) is trading at is $0.54, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Landos Biophma(LABP)评级被下调，目标价为0.20美元至0.10美元。Landos Biophma(LABP)目前的交易价格为0.54美元，超出了分析师的预测区间。